 |
Prospector
Profile
07.1506
|
| |
| Cyplasin Biomedical, Inc. |
NAICS |
541710 |
| Unit 131, Advanced Technology Center
Edmonton, Alberta, Canada T6N 1G1 |
Description |
Biotechnology |
| (780) 469-2975 |
Employees |
2 |
|
Revenue |
(mil) |
1.3580 |
| |
Income |
(mil) |
0.0010 |
| |
Assets |
(mil) |
0.3780 |
| |
Liability |
(mil) |
0.3130 |
| |
(for the year ended 2007-01-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Cyplasin Biomedical, Inc. had a net loss of $376,319 for the six months ended July 31, 2007, compared to a net income of $33,284 during the same period last year. For the three months ended July 31, 2007, the Company had a $160,584 net loss, compared to a $13,559 net income reported during the three months ended July 31, 2006. As a result of its recurring losses, the Company's balance sheet at July 31, 2007 showed an accumulated deficit of $328,975.
|
| |
|
Intellectual Property:
The Company Chief Scientidic Office, Prof. Christian Petzelt discovered the cyplasin protein’s selective cytotoxic effects for cancer cells in 1997 and received a US patent (number 6,171,818) on January 9, 2001, relating to a protein having anti-tumor activity, while having a DNA encoding for the same, plus having a process for the preparation of the same with application of methods for treating malignancies such as cancers with the same. Also, the Company is currently involved in the patent applications for Cytotoxic cyplasin of the sea hare, Aplysia punctata, cDNA cloning and expression of bioreactive recombinants - PCT/EP02/14511. It has also filed for registration of the trademarks Cyplasin™ and Cyplasin-SC™. [SEC Filing 10-KSB 05-01-07]
|
| |
|
Description:
The Company is developing a novel therapeutic, recombinant protein called Cyplasin™.
|
| |
|
Officers:
Garth Likes (Pres., CEO & Dir.); Christian Petzelt (Chief Scientific Officer & Dir.); Geoffrey Galley (Dir.); Lennie Ryer (Dir.); Luc Mainville (Dir.)
|
| |
|
Auditor:
Dale Matheson Carr-Hilton Labonte LLP
|
| |
|
Securities:
Common Stock-Symbol CYPL.OB; OTC BB;
38,984,000 common shares outstanding as of September 10, 2007.
|
| |
| |
| |
| return to main page |
|
|
